Alert: Major Price Advance (12/14/23)-Fate Therapeutics Inc (NASDAQ: FATE).


Fate Therapeutics Inc (NASDAQ: FATE) stock enjoyed a major increase of 11.2% on 12/14/23. The shares closed at $2.98. Moreover, trading volume in this advance was exceptionally high at 206% of normal. The stock has been extremely weak relative to the market over the last nine months but has risen 24.2% during the last week.


Current PriceTarget Research Rating

FATE’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.

Fate Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Fate Therapeutics has a very high Appreciation Score of 89 but a very low Power Rating of 10, and the Neutral Value Trend Rating results.

Rating Review

In light of this very positive price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.

Be the first to comment

Leave a Reply

Your email address will not be published.